Abstract:PURPOSE: We compare Prostate Health Index, Prostate Health Index density, and PSA density in predicting clinically significant prostate cancer in MRI-guided prostate biopsy.MATERIALS AND METHODS: This is a multicenter evaluation of prospectively maintained prostate biopsy databases at 10 urology centers. Men with Prostate Health Index and MRI-guided targeted and systematic prostate biopsy performed and without prior prostate cancer diagnosis were included. The additional value of PSA density, Prostate Health Index, and Prostate Health Index density to MRI Prostate Imaging Reporting & Data System score was evaluated with multivariable analyses, area under the curve, and decision curve analyses. The proportion of unnecessary biopsies that can be avoided are estimated for clinically significant prostate cancer (International Society of Urological Pathology group ≥2 prostate cancer).RESULTS: A total of 1,215 men were analyzed. Prostate cancer and clinically significant prostate cancer were diagnosed in 51% (617/1,215) and 35% (422/1,215) of men, respectively. Clinically significant prostate cancer was diagnosed in 4.4% (3/68), 15% (72/470), 39% (176/446), and 74% (171/231) of highest Prostate Imaging Reporting & Data System score of 2, 3, 4, and 5 lesions, respectively. In multivariable analyses, independent predictors for clinically significant prostate cancer detection included Prostate Health Index (OR 1.04), prostate volume (OR 0.97), and Prostate Imaging Reporting & Data System score 4 (OR 2.81) and 5 (OR 8.34). Area under the curve for clinically significant prostate cancer of Prostate Imaging Reporting & Data System + Prostate Health Index density (0.85) was superior to Prostate Imaging Reporting & Data System + PSA density (0.81), Prostate Health Index density (0.81), Prostate Health Index (0.78), Prostate Imaging Reporting & Data System (0.76), PSA density (0.72), and PSA (0.60) in the whole cohort, and the superiority of Prostate Health Index density was also observed in Prostate Imaging Reporting & Data System 3 lesions. Decision curve analysis showed Prostate Health Index density achieving the best net clinical benefit in Prostate Imaging Reporting & Data System 3 or 4 cases. Among Prostate Imaging Reporting & Data System 3 lesions, using cutoffs of PSA density 0.15, Prostate Health Index 38.0, and Prostate Health Index density 0.83 could reduce 58%, 67%, and 72% of unnecessary biopsies, respectively.CONCLUSIONS: Prostate Health Index density outperformed Prostate Health Index or PSA density in clinically significant prostate cancer detection in men with multiparametric MRI performed, and further reduced unnecessary biopsies in Prostate Imaging Reporting & Data System 3 lesions.

Consistent predictive ability of prostate‐specific antigen density prediction model for clinically significant prostate cancer across age strata

Optimizing Prostate Cancer Accumulating Model: Combined PI-RADS V2 with Prostate Specific Antigen and Its Derivative Data.

Improving the Detection Rate of Prostate Cancer in the Gray Zone of PI-RADS V2 and Serum Tpsa by Using Prostate-Specific Antigen–age Volume

Prostate Imaging-Reporting and Data System Version 2 in Combination with Clinical Parameters for Prostate Cancer Detection: a Single Center Experience

A multicenter retrospective study on evaluation of predicative factors for positive biopsy of prostate cancer in real-world setting

Prostate Age Gap (PAG): An MRI surrogate marker of aging for prostate cancer detection

Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer

Evaluating the Utility of Prostate-Specific Antigen Density in Risk Stratification of PI-RADS 3 Peripheral Zone Lesions on Non-Contrast-Enhanced Prostate MRI: An Exploratory Single-Institution Study

PI-RADS v2.1 and PSAD for the prediction of clinically significant prostate cancer among patients with PSA levels of 4–10 ng/ml

Predicting clinically significant prostate cancer following suspicious mpMRI: analyses from a high-volume center

Unlocking Precision Enhancing Prostate Cancer Detection and Reducing Unnecessary Biopsies with Combined Prostate-Specific Antigen Density and PI-RADS Score

Prostate Health Index Density Outperforms PSA Density in the Diagnosis of Clinically Significant Prostate Cancer in Equivocal MRI Prostates: A Multicenter Evaluation

Combining prostate-specific antigen density with prostate imaging reporting and data system score version 2.1 to improve detection of clinically significant prostate cancer: A retrospective study

Biparametric prostate MRI and clinical indicators predict clinically significant prostate cancer in men with "gray zone" PSA levels

Evaluation of PSA-age Volume Score in Predicting Prostate Cancer in Chinese Population

Prostate extracellular vesicles and prediction of clinically significant prostate cancer: A prospective single-institution pilot study.

Prostate Health Index Density Outperforms Prostate-specific Antigen Density in the Diagnosis of Clinically Significant Prostate Cancer in Equivocal Magnetic Resonance Imaging of the Prostate: A Multicenter Evaluation.

Prostate-specific antigen (PSA), PSA density and age-adjusted PSA reference values in screening for prostate cancer--a study of a randomly selected population of 2,400 men.

The Role of PSA Density among PI-RADS v2.1 Categories to Avoid an Unnecessary Transition Zone Biopsy in Patients with PSA 4-20 ng/mL

Clinical and Radiological Factors for Predicting Clinically Significant Prostate Cancer in Biopsy-Naive Patients With PI-RADS 3 Lesions

PSA Density Help to Identify Patients With Elevated PSA Due to Prostate Cancer Rather Than Intraprostatic Inflammation: A Prospective Single Center Study